Results: The intraoperative course was successful in all patients, and no perioperative death or complication related to laparoscopic HIPPC was documented. The median follow-up period was 9 months, and the median survival was 7.5 months for all patients. Patients in the Ra/L-OHP group had a median survival of 8.7 months, the Ra/DDP group had a median survival of 5.6 months, and the Ra/MMC group had a median survival of 7.5 months. Patients′ median survival in the Ra/L-OHP group and Ra/MMC group was significantly longer than in the Ra/DDP group (P < .00). No significant difference was found in total remission rate of ascites, increase in the Karnofsky Performance Scale, and incidence rate of port-site metastases among the three groups.



结果：所有患者手术都很成功,没有围手术期死亡记录和与腹腔镜HIPPC有关的并发症记录。平均随访期为9个月，所有患者平均生存7.5个月。雷替曲塞与奥利沙铂组患者平均生存8.7个月，雷替曲塞与顺铂组患者平均生存5.6个月，雷替曲塞与丝裂霉素C组患者平均生存7.5个月。雷替曲塞与奥利沙铂组的患者与雷替曲塞与丝裂霉素C组患者生存时间显著长于雷替曲塞与顺铂组患者（P<0.00)。三组患者在腹水总缓解率,远期生活质量水平的提高和穿刺孔转移发生率上没有显著性差异。



Conclusions: Laparoscopy-assisted HIPPC provides modest yet encouraging efficacy for malignant ascites secondary to disseminated GC.Our preliminary data indicate that the chemotherapeutic combination of Ra/L-OHP and Ra/MMC might be more beneficial compared with Ra/DDP in terms of patients′ survival.



结论：胃腔镜辅助型体腔热灌注化疗法对弥散性胃癌引起的恶性腹水提供了适度而鼓舞人心的疗效。我们的原始数据表明雷替曲塞搭配奥利沙铂和雷替曲塞搭配丝裂霉素C比起雷替曲塞搭配顺铂更有益于患者生存。